Abstract
Introduction: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity associated with the persistent presence of antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-β2 glycoprotein I antibodies (aβ2GPI). Areas covered: APS is considered as the most common acquired hypercoagulation state of autoimmune origin in children. Unfortunately, data about incidence, prevalence, thrombosis risk and effective treatment in paediatric APS are limited and unmethodical. Expert commentary: This review summarizes recent clinical, laboratory and therapy characterization of paediatric APS and emphasizes the differences between paediatric and adult populations.
| Original language | English |
|---|---|
| Pages (from-to) | 977-985 |
| Number of pages | 9 |
| Journal | Expert Review of Hematology |
| Volume | 9 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2 2016 |
Keywords
- De novo aPL
- neonatal thrombosis
- Paediatric antiphospholipid syndrome
- Paediatric CAPS
- Ped APS Registry
- thrombosis in children
ASJC Scopus subject areas
- Hematology